Thursday, January 14, 2016
Shares of Marksans Pharma fell by nearly 20 per cent on the Bombay Stock Exchange (BSE) after the company's Goa plant failed to clear an inspection by the UK drug regulator, media reports said. The company got a notice of deficiency from UK MHRA related to the matter. The drug regulator is said to have found violations in goods manufacturing practices (GMP) norms in the Goa plant. Following the development, shares of the company dropped 19.96 per cent to Rs 75.80 a piece on Bombay Stock Exchange. Shares of the company dipped 19.98 per cent to Rs 75.70 a piece on National Stock Exchange. Meanwhile, the broader benchmark BSE Sensex was trading at 24,579.72, down 102.31 points, or 0.41 per cent, at 11:30 hours.